Therefore, SLNs conjugated with RAGE could offer a potential therapeutic strategy for enhancing the anti-tumor efficacy of cytotoxic agents over cancer cells, without exerting undesirable effects on non-tumour cells. This evidence concerns the gene AGER and cancer.